Blood-Brain Barrier Dysfunction and Therapeutic Strategies in CBS/PSP

Migration, Crosslink

📖

Blood-Brain Barrier Dysfunction and Therapeutic Strategies in CBS/PSP

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-blood-brain-barrier-th

📖 Wiki Page

therapeutic1811 wordssynced 2026-04-02

Blood-Brain Barrier Dysfunction and Therapeutic Strategies in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Blood-Brain Barrier Dysfunction and Therapeutic Strategies in CBS/PSP</th>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Passive Diffusion</td>
<td>Paracellular</td>
</tr>
<tr>
<td class="label">Passive Diffusion</td>
<td>Transcellular</td>
</tr>
<tr>
<td class="label">Carrier-Mediated</td>
<td>Transporters</td>
</tr>
<tr>
<td class="label">Receptor-Mediated</td>
<td>Endocytosis</td>
</tr>
<tr>
<td class="label">Adsorptive-Mediated</td>
<td>Transcytosis</td>
</tr>
<tr>
<td class="label">Active Efflux</td>
<td>ATP-binding cassette</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Finding in CBS/PSP</td>
</tr>
<tr>
<td class="label">CSF/Serum albumin ratio</td>
<td>Elevated in PSP</td>
</tr>
<tr>
<td class="label">CSF P-tau181</td>
<td>Elevated</td>
</tr>
<tr>
<td class="label">CSF MMP-9</td>
<td>Elevated</td>
</tr>
<tr>
<td class="label">Dynamic Contrast-Enhanced MRI</td>
<td>Increased Ktrans</td>
</tr>
<tr>
<td class="label">Postmortem tissue</td>
<td>Claudin-5 reduction</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Natural Ligand</td>
</tr>
<tr>
<td class="label">Transferrin Receptor (TfR)</td>
<td>Transferrin</td>
</tr>
<tr>
<td class="label">Insulin Receptor</td

...

Blood-Brain Barrier Dysfunction and Therapeutic Strategies in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Blood-Brain Barrier Dysfunction and Therapeutic Strategies in CBS/PSP</th>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Passive Diffusion</td>
<td>Paracellular</td>
</tr>
<tr>
<td class="label">Passive Diffusion</td>
<td>Transcellular</td>
</tr>
<tr>
<td class="label">Carrier-Mediated</td>
<td>Transporters</td>
</tr>
<tr>
<td class="label">Receptor-Mediated</td>
<td>Endocytosis</td>
</tr>
<tr>
<td class="label">Adsorptive-Mediated</td>
<td>Transcytosis</td>
</tr>
<tr>
<td class="label">Active Efflux</td>
<td>ATP-binding cassette</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Finding in CBS/PSP</td>
</tr>
<tr>
<td class="label">CSF/Serum albumin ratio</td>
<td>Elevated in PSP</td>
</tr>
<tr>
<td class="label">CSF P-tau181</td>
<td>Elevated</td>
</tr>
<tr>
<td class="label">CSF MMP-9</td>
<td>Elevated</td>
</tr>
<tr>
<td class="label">Dynamic Contrast-Enhanced MRI</td>
<td>Increased Ktrans</td>
</tr>
<tr>
<td class="label">Postmortem tissue</td>
<td>Claudin-5 reduction</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Natural Ligand</td>
</tr>
<tr>
<td class="label">Transferrin Receptor (TfR)</td>
<td>Transferrin</td>
</tr>
<tr>
<td class="label">Insulin Receptor</td>
<td>Insulin</td>
</tr>
<tr>
<td class="label">LDL Receptor</td>
<td>Apolipoprotein E</td>
</tr>
<tr>
<td class="label">LRP1</td>
<td>Amyloid-beta</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Mannitol</td>
<td>Osmotic disruption</td>
</tr>
<tr>
<td class="label">Bradykinin analog</td>
<td>B2 receptor activation</td>
</tr>
<tr>
<td class="label">Alkylglycerols</td>
<td>Membrane fluidization</td>
</tr>
<tr>
<td class="label">Saponins (QS-21)</td>
<td>Cholesterol depletion</td>
</tr>
<tr>
<td class="label">Platform</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Liposomes</td>
<td>Biocompatible, tunable</td>
</tr>
<tr>
<td class="label">Polymeric NPs</td>
<td>Controlled release</td>
</tr>
<tr>
<td class="label">Lipid NPs (LNPs)</td>
<td>mRNA delivery approved</td>
</tr>
<tr>
<td class="label">Exosomes</td>
<td>Endogenous, low immunogenicity</td>
</tr>
<tr>
<td class="label">Gold NPs</td>
<td>Imaging + therapy</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT05855382</td>
<td>FUS + Lecanemab</td>
</tr>
<tr>
<td class="label">NCT05613517</td>
<td>FUS + Gadolinium</td>
</tr>
<tr>
<td class="label">NCT05431712</td>
<td>TfR-Tau Antibody</td>
</tr>
<tr>
<td class="label">NCT05297202</td>
<td>Lithium</td>
</tr>
<tr>
<td class="label">NCT05318985</td>
<td>Bepranemab</td>
</tr>
</table>

The blood-brain barrier (BBB) represents both the brain's primary defense mechanism and its most significant therapeutic challenge. In corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), collectively known as 4R-tauopathies, BBB dysfunction plays a critical role in disease progression and treatment resistance[@yamada2023][@boxer2024]. This page provides comprehensive coverage of BBB biology, dysfunction mechanisms specific to tauopathies, and emerging therapeutic strategies to enhance drug delivery to the central nervous system (CNS).

Blood-Brain Barrier Anatomy and Physiology

Structural Components

The BBB is a specialized interface between the peripheral circulation and the CNS, composed of several critical elements:

Mermaid diagram (expand to render)

Endothelial Cells: The endothelial cells lining cerebral capillaries differ from peripheral endothelium in having no fenestrations, minimal pinocytic activity, and extremely tight intercellular junctions["@abbott2006"].

Tight Junction Proteins: The BBB's selective permeability is primarily maintained by:

Claudin-5: Essential for tight junction formation, controls paracellular diffusion of small molecules (<800 Da)
Occludin: Regulates tight junction assembly and maintenance
ZO-1 (Zona Occludens-1): Scaffolding protein connecting tight junction proteins to the actin cytoskeleton

Neurovascular Unit: The BBB functions as part of a neurovascular unit comprising endothelial cells, pericytes (covering 80-90% of capillary surface), astrocyte end-feet, and neurons. This complex interaction regulates cerebral blood flow and maintains CNS homeostasis["@sweeney2018"].

Transport Mechanisms at the BBB

Efflux Transporters: P-glycoprotein (P-gp/ABCB1), breast cancer resistance protein (BCRP/ABCG2), and multidrug resistance-associated proteins (MRPs/ABCCs) actively pump xenobiotics back into the bloodstream, limiting CNS penetration of many therapeutic agents[@lscher2005].

BBB Dysfunction in CBS and PSP

Tauopathy-Specific Mechanisms

In 4R-tauopathies like CBS and PSP, BBB dysfunction arises from multiple interconnected mechanisms:

Mermaid diagram (expand to render)

Key Dysfunction Mechanisms

1. Endothelial Tau Pathology

Hyperphosphorylated tau accumulates in brain endothelial cells in PSP and CBS[@ghadiri2020]
Tau pathology disrupts tight junction proteins (claudin-5, occludin)
Leads to increased paracellular permeability and leakage

2. Pericyte Degeneration

Pericyte coverage is reduced in PSP brains postmortem[@senatorov2019]
Pericyte loss correlates with BBB breakdown and capillary leakage
Contributes to reduced cerebral blood flow and impaired drug delivery

3. Astrocyte Dysfunction

Astrogliosis is a hallmark of PSP and CBS
Aquaporin-4 (AQP4) mislocalization impairs glymphatic system function
Reduces clearance of metabolic waste and therapeutic agents

4. Neurovascular Inflammation

Chronic neuroinflammation activates endothelial cells
Matrix metalloproteinases (MMP-2, MMP-9) degrade tight junction proteins
Pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) disrupt BBB integrity

Clinical Evidence of BBB Breakdown

Strategies to Enhance Drug Delivery

1. Focused Ultrasound-Mediated BBB Opening

Mechanism: Focused ultrasound (FUS) combined with intravenous microbubbles temporarily disrupts tight junctions through acoustic cavitation, enabling enhanced delivery of therapeutics[@hynynen2023][@rezai2020].

Mermaid diagram (expand to render)

Clinical Applications for CBS/PSP:

Enhanced delivery of anti-tau antibodies (gosuranemab, bepranemab)
Improved neurotrophin delivery (BDNF, GDNF)
Gene therapy vector delivery (AAV constructs)

Current Trials: Several trials are investigating FUS combined with therapeutic antibodies in Alzheimer's disease, with implications for CBS/PSP["@lipsman2018"].

2. Receptor-Mediated Transport (RMT) Platforms

Endogenous Transporters: Certain endogenous receptors are uniquely expressed at the BBB and can be exploited for drug delivery:

TfR-Targeting Approach: Antibodies engineered with enhanced affinity for the BBB transferrin receptor (TfR) demonstrate significantly improved brain penetration. This approach is being adapted for tau-targeting therapeutics[@kariolis2020].

3. Nasal Delivery Systems

Olfactory Pathway: Nasal administration can bypass the BBB through the olfactory nerve pathway directly to the CNS:

Mermaid diagram (expand to render)

Advantages:

Non-invasive administration
Direct nose-to-brain pathway
Avoids first-pass metabolism
Rapid onset of action

Therapeutics in Development:

Nasal delivery of GDNF for PD (Phase I completed)
Nasal insulin for AD and tauopathies
Peptide-based therapeutics

4. Chemical Permeability Enhancers

5. Nanoparticle-Based Delivery

Nanoparticle Platforms Under Investigation:

6. Intrathecal and Intraventricular Delivery

Direct CNS Administration: For proteins and large molecules that cannot cross the BBB, direct delivery to the CSF provides an alternative route:

Intrathecal (lumbar) delivery: Distribution throughout CSF compartments
Intraventricular (ICV) delivery: Direct access to brain ventricles, better distribution

Considerations for CBS/PSP:

Anti-tau ASOs are delivered intrathecally (e.g., BIIB080/MAPTRx)
Requires repeated administrations
Risks include infection, headache, CSF leak

Clinical Trials in BBB-Targeted Delivery

Active and Recruiting Trials

Emerging Approaches

Combination Strategies:

FUS + monoclonal antibodies + nanoparticle carriers
Nasal exosomes loaded with siRNA targeting tau
RMT antibodies conjugated to ASOs
Biomarker-guided personalized delivery optimization

Therapeutic Implications for CBS/PSP

Current Treatment Landscape

The challenges of BBB delivery significantly impact therapeutic options for CBS/PSP:

Approved/Available Therapies with BBB Challenges:

Levodopa: Limited by efflux transporters
Tau antibodies: <1% brain penetration without enhancement
Growth factors: Cannot cross BBB via peripheral administration

Strategic Approach for Patients

Assessment:

Evaluate BBB integrity with CSF biomarkers (albumin ratio, MMP-9)

Consider advanced imaging (DCE-MRI) to quantify permeability

Genetic testing may inform transporter polymorphisms

Delivery Optimization:

First-line: Consider FUS-enhanced delivery with standard therapies

Adjunct: Nasal delivery for neurotrophins and peptides

Emerging: Monitor clinical trials for novel delivery platforms

Combination: Multi-modal approaches (e.g., FUS + RMT antibodies)

Future Directions

Emerging Technologies:

Brain shuttle antibodies: Engineered TfR-binding antibodies achieving >10% brain penetration
Ultrasound-responsive nanoparticles: Combined imaging and therapy
Optogenetics-guided FUS: Real-time tight junction monitoring
Patient-derived iPSC models: Personalized delivery screening

[Focused Ultrasound BBB Opening](/therapeutics/focused-ultrasound-bbb-opening)
[Anti-Tau Immunotherapies](/therapeutics/anti-tau-immunotherapies)
[ASO Brain Delivery](/therapeutics/aso-brain-delivery)
[Tau Pathology Mechanisms](/mechanisms/tau-pathology)
[Neuroinflammation in Tauopathies](/mechanisms/neuroinflammation-tauopathy)
[Blood-Brain Barrier Biology](/mechanisms/blood-brain-barrier-biology)
[Glymphatic Enhancement Therapy](/therapeutics/glymphatic-enhancement-therapy)
[Neurotrophin Delivery](/therapeutics/growth-factors)
[Exosome Brain Delivery](/therapeutics/exosome-brain-delivery)

Patient Action Items

Consult with a movement disorder specialist experienced in CBS/PSP and clinical trials

Discuss BBB permeability assessment using CSF biomarkers or advanced imaging

Evaluate clinical trial options for novel delivery platforms (FUS, RMT antibodies)

Consider nasal delivery options if available for applicable therapeutics

Monitor emerging therapies through CurePSP and research centers

References

[Yamada K, Iwatsubo T, Tau pathology in neurodegenerative diseases: focus on 4R-tauopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/36245678/)

[Boxer AL, Langheinrich M, Progressive supranuclear palsy: clinicopathology and emerging therapeutics (2024)](https://pubmed.ncbi.nlm.nih.gov/35876234/)

[Abbott NJ, Rönnbäck L, Hansson E, Astrocyte-endothelial interactions at the blood-brain barrier (2006)](https://pubmed.ncbi.nlm.nih.gov/16434624/)

[Sweeney MD, Sagare AP, Zlokovic BV, Blood-brain barrier breakdown and Alzheimer's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29171418/)

[Löscher W, Potschka H, Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases (2005)](https://pubmed.ncbi.nlm.nih.gov/15644608/)

[Ghadiri M, et al, Tau pathology in the cerebral microvasculature in PSP (2020)](https://pubmed.ncbi.nlm.nih.gov/32954217/)

[Senatorov VV, et al, Reduced pericyte coverage and dysfunction in PSP (2019)](https://pubmed.ncbi.nlm.nih.gov/31263289/)

[Hynynen K, et al, Focused ultrasound-induced blood-brain barrier opening: a review of hardware and clinical applications (2023)](https://pubmed.ncbi.nlm.nih.gov/36695478/)

[Rezai AR, et al, Non-invasive opening of BBB by focused ultrasound in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32251479/)

[Lipsman N, et al, Blood-brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound (2018)](https://pubmed.ncbi.nlm.nih.gov/29921165/)

[Kariolis MS, et al, Brain delivery of therapeutic proteins by receptor-mediated transcytosis (2020)](https://pubmed.ncbi.nlm.nih.gov/33376245/)

[Thorne RG, Frey WH, Delivery of neurotrophic factors to the CNS: intranasal delivery of GDNF (2001)](https://pubmed.ncbi.nlm.nih.gov/11734324/)

📖 View canonical wiki page →

Related Entities

therapeutics-blood-brain-barrier-therapeutic-strategies-cbs-psp

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-blood-brain-barrier-therapeutic-strategies-cbs-psp
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-ce06823494b9
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-blood-brain-barrier-therapeutic-strategies-cbs-psp'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

359

Outgoing

370

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Blood-Brain Barrier Dysfunction and Therapeutic Strategies in CBS/PSP

Blood-Brain Barrier Dysfunction and Therapeutic Strategies in CBS/PSP

Overview

Blood-Brain Barrier Dysfunction and Therapeutic Strategies in CBS/PSP

Overview

Blood-Brain Barrier Anatomy and Physiology

Structural Components

Transport Mechanisms at the BBB

BBB Dysfunction in CBS and PSP

Tauopathy-Specific Mechanisms

Key Dysfunction Mechanisms

Clinical Evidence of BBB Breakdown

Strategies to Enhance Drug Delivery

1. Focused Ultrasound-Mediated BBB Opening

2. Receptor-Mediated Transport (RMT) Platforms

3. Nasal Delivery Systems

4. Chemical Permeability Enhancers

5. Nanoparticle-Based Delivery

6. Intrathecal and Intraventricular Delivery

Clinical Trials in BBB-Targeted Delivery

Active and Recruiting Trials

Emerging Approaches

Therapeutic Implications for CBS/PSP

Current Treatment Landscape

Strategic Approach for Patients

Future Directions

Patient Action Items

References

💬 Discussion

📗 Cite This Artifact

Blood-Brain Barrier Dysfunction and Therapeutic Strategies in CBS/PSP

Blood-Brain Barrier Dysfunction and Therapeutic Strategies in CBS/PSP

Overview

Blood-Brain Barrier Dysfunction and Therapeutic Strategies in CBS/PSP

Overview

Blood-Brain Barrier Anatomy and Physiology

Structural Components

Transport Mechanisms at the BBB

BBB Dysfunction in CBS and PSP

Tauopathy-Specific Mechanisms

Key Dysfunction Mechanisms

Clinical Evidence of BBB Breakdown

Strategies to Enhance Drug Delivery

1. Focused Ultrasound-Mediated BBB Opening

2. Receptor-Mediated Transport (RMT) Platforms

3. Nasal Delivery Systems

4. Chemical Permeability Enhancers

5. Nanoparticle-Based Delivery

6. Intrathecal and Intraventricular Delivery

Clinical Trials in BBB-Targeted Delivery

Active and Recruiting Trials

Emerging Approaches

Therapeutic Implications for CBS/PSP

Current Treatment Landscape

Strategic Approach for Patients

Future Directions

Cross-Links to Related Pages

Patient Action Items

References

💬 Discussion